- Home
- RVNC
as 07-26-2024 4:00pm EST
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NASHVILLE |
| Market Cap: | 292.5M | IPO Year: | 2014 |
| Target Price: | $12.00 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.30 - $23.74 | Next Earning Date: | 08-06-2024 |
| Revenue: | $236,645,000 | Revenue Growth: | 54.59% |
| Revenue Growth (this year): | 20.63% | Revenue Growth (next year): | 34.80% |
Stock Insider Trading Activity of Revance Therapeutics Inc. (RVNC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Jordan Erica | RVNC | Chief Commercial Officer | Apr 16 '24 | Sell | $3.80 | 2,392 | $9,096.30 | 114,864 | SEC Form 4 |
| Sjuts Dustin S | RVNC | President | Mar 15 '24 | Sell | $5.04 | 9,211 | $46,446.47 | 167,550 | SEC Form 4 |
| Moxie Dwight | RVNC | CLO & GC | Mar 15 '24 | Sell | $5.04 | 8,125 | $40,971.13 | 137,815 | SEC Form 4 |
| Schilke Tobin | RVNC | CFO | Mar 15 '24 | Sell | $5.04 | 9,361 | $47,203.78 | 192,666 | SEC Form 4 |
| Foley Mark J | RVNC | CEO | Mar 6 '24 | Buy | $6.98 | 30,000 | $209,400.00 | 1,015,468 | SEC Form 4 |
Latest Revance Therapeutics Inc. News
RVNC Breaking Stock News: Dive into RVNC Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
2 months ago
Revance to Participate in Upcoming Investor Conferences
Zacks
2 months ago
Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Insider Monkey
3 months ago
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2024 Earnings Call Transcript
GuruFocus.com
3 months ago
Revance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ...
MT Newswires
3 months ago
Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating
MT Newswires
3 months ago
Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating
Zacks
3 months ago
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
Compare RVNC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RVNC Revance Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.